,Rank,NCT Number,Title,Acronym,Status,Study Results,Conditions,Interventions,Outcome Measures,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,Funded Bys,Study Type,Study Designs,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents,URL,class,nmf_pred
0,1,NCT00523276,SARS Survivor Evaluations,,Withdrawn,No Results Available,Coronavirus (SARS-CoV),,"Positive serology, SARS CoV",National Institute of Allergy and Infectious Diseases (NIAID),All,"4 Years and older   (Child, Adult, Older Adult)",,0.0,NIH,Observational,Observational Model: Family-Based|Time Perspective: Cross-Sectional,06-0048,,June 2011,June 2011,"August 31, 2007",,"April 29, 2013","Beijing Ditan Hospital, Beijing, Beijing, China|Beijing You'An Hospital, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT00523276,0,0
1,2,NCT00533741,SARS Coronavirus Vaccine (SARS-CoV),,Withdrawn,No Results Available,Coronavirus (SARS-CoV),Drug: Aluminum hydroxide|Drug: Placebo|Biological: SARS-CoV,"Frequency and description of serious adverse events (SAEs).|Frequency of significant increases in serum antibody to CoV S protein in Enzyme Linked Immunosorbent Assay (ELISA) and in neutralization tests, and increases in Geometric Mean Titers (GMT)s in sera.|Frequency and severity of solicited injection site and systemic signs and symptoms and unsolicited adverse events (AE) / SAEs.|Frequency of significant serum antibody increases and increases in Geometric Mean Titers (GMT)s, as measured in neutralizing antibody tests and an ELISA against SARS-CoV S protein.",National Institute of Allergy and Infectious Diseases (NIAID),All,18 Years to 40 Years   (Adult),Phase 1,0.0,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",07-0021,,January 2012,January 2012,"September 21, 2007",,"December 3, 2012","Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00533741,0,0
2,3,NCT01376765,"Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study",,Withdrawn,No Results Available,SARS,Drug: Aluminum hydroxide adjuvant (Alhydrogel®)|Other: Phosphate buffered saline Placebo|Biological: Recombinant S protein SARS vaccine,"Occurrence of solicited local and systemic adverse events (AE)within 8 days after vaccination (Days 0-7 and Days 28-35)|Incidence of vaccine-related serious adverse events (SAEs) throughout the duration of the study.|Occurrence of laboratory abnormalities at 8 days after vaccination (Days 8 and 36)|Immunogenicity: Proportion of subjects achieving a detectable serum neutralizing antibody titer against SARS-CoV in each immunized group 28 days after receipt of the second dose of vaccine (approximately Day 56)|Immunogenicity: GMT of neutralizing antibody titers against SARS-CoV in each immunized group 28 days after receipt of the second dose of vaccine (Day 56). Measurement will include the Day 56 GMT and the mean fold change (GMT ratio Day 56:Day 0)|Comparison of rates of unsolicited AEs related to vaccine for all subjects between treatment groups and in the combined cohorts receiving vaccine with aluminum hydroxide adjuvant compared with those receiving vaccine with no adjuvant.|Immunogenicity: Geometric Mean Titer (GMT) of antibody titers (IgG ELISA for S protein of SARS-CoV) 28 days after receipt of the second dose of vaccine (Day 56) at each vaccine dose level, with and without adjuvant",National Institute of Allergy and Infectious Diseases (NIAID),All,18 Years to 40 Years   (Adult),Phase 1,0.0,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",09-0100,,,,"June 20, 2011",,"February 15, 2013","University of Iowa - Infectious Disease Clinic, Iowa City, Iowa, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01376765,0,0
3,4,NCT00066209,Investigating Severe Acute Respiratory Syndrome (SARS),,Completed,No Results Available,SARS Virus,,,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Older Adult",,400.0,NIH,Observational,,030240|03-I-0240,"August 4, 2003",,"May 24, 2007","August 6, 2003",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00066209,0,0
4,5,NCT00342524,Collection of Convalescent SARS Plasma by Apheresis,,Completed,No Results Available,Severe Acute Respiratory Syndrome|SARS,,,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",,,NIH,Observational,,999905192|05-I-N192,"July 6, 2005",,"February 8, 2007","June 21, 2006",,"July 2, 2017","The Chinese University of Hong Kong, Hong Kong, China",,https://ClinicalTrials.gov/show/NCT00342524,0,0
5,6,NCT03463031,Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR),GSP 301-305,Completed,Has Results,Seasonal Allergic Rhinitis (SAR),Drug: GSP 301 NS|Drug: GSP 301 Placebo NS,Change From Baseline in Average AM and PM Subject-reported 12-hour Reflective Total Nasal Symptom Score ( rTNSS) Over the 14-day Treatment Period|Change From Baseline in Average AM and PM Subject-reported 12-hour Instantaneous Total Nasal Symptom Score (iTNSS) Over the 14-day Treatment Period.|Change From Baseline in the Overall Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) Score on Day 15 (Visit 4)|Change From Baseline in Average AM and PM Subject-reported 12-hour Reflective Total Ocular Symptom Score (rTOSS) Over the 14-day Treatment Period.,Glenmark Specialty S.A.,All,6 Years to 11 Years   (Child),Phase 3,446.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GSP 301-305,"March 16, 2018","November 14, 2018","November 14, 2018","March 13, 2018","October 8, 2019","October 8, 2019","Glenmark Investigational Site 18, Mission Viejo, California, United States|Glenmark Investigational Site 32, Ontario, California, United States|Glenmark Investigational Site 30, Paramount, California, United States|Glenmark Investigational Site 17, San Diego, California, United States|Glenmark Investigational Site 21, Colorado Springs, Colorado, United States|Glenmark Investigational Site 13, Marietta, Georgia, United States|Glenmark Investigational Site 26, Savannah, Georgia, United States|Glenmark Investigational Site 28, Louisville, Kentucky, United States|Glenmark Investigational Site 14, Baltimore, Maryland, United States|Glenmark Investigational Site 19, Bethesda, Maryland, United States|Glenmark Investigational Site 25, Ypsilanti, Michigan, United States|Glenmark Investigational Site 12, Columbia, Missouri, United States|Glenmark Investigational Site 10, Rolla, Missouri, United States|Glenmark Investigational Site 27, Warrensburg, Missouri, United States|Glenmark Investigational Site 15, Omaha, Nebraska, United States|Glenmark Investigational Site 3, High Point, North Carolina, United States|Glenmark Investigational Site 8, Raleigh, North Carolina, United States|Glenmark Investigational Site 11, Cincinnati, Ohio, United States|Glenmark Investigational Site 29, Cincinnati, Ohio, United States|Glenmark Investigational Site 2, Edmond, Oklahoma, United States|Glenmark Investigational Site 33, Tulsa, Oklahoma, United States|Glenmark Investigational Site 4, Medford, Oregon, United States|Glenmark Investigational Site 6, Spartanburg, South Carolina, United States|Glenmark Investigational Site 5, Austin, Texas, United States|Glenmark Investigational Site 24, Kerrville, Texas, United States|Glenmark Investigational Site 1, New Braunfels, Texas, United States|Glenmark Investigational Site 7, San Antonio, Texas, United States|Glenmark Investigational Site 9, San Antonio, Texas, United States|Glenmark Investigational Site 20, Waco, Texas, United States|Glenmark Investigational Site 31, Waco, Texas, United States|Glenmark Investigational Site 22, Draper, Utah, United States|Glenmark Investigational Site 23, Greenfield, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT03463031/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT03463031/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03463031,0,0
6,7,NCT03443102,Long-term Assessment of Organ Functions Among Survivors of Severe Acute Respiratory Syndrome,,Recruiting,No Results Available,SARS Virus|Long-Term Survivors,,All-cause disability|Cardiopulmonary function|Life Life quaities mental distress,Peking University People's Hospital,All,"Child, Adult, Older Adult",,150.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,2018PHB010-01,"January 25, 2018","July 1, 2018","December 1, 2018","February 22, 2018",,"February 26, 2018","Peking University People's Hospital, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT03443102,0,0
7,8,NCT02870205,Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR),GSP 301-304,Completed,Has Results,Seasonal Allergic Rhinitis (SAR),Drug: GSP 301 NS|Drug: GOM-NS|Drug: GMM-2 NS|Drug: GSP 301 placebo NS,Change From Baseline in Average AM and PM Subject-reported 12-hour Reflective Total Nasal Symptom Score (rTNSS),Glenmark Specialty S.A.,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1176.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GPL/CT/2015/004/III|Study Number: GSP 301-304,August 2016,January 2017,January 2017,"August 17, 2016","April 6, 2018","April 6, 2018","Investigational Site 406, Mission Viejo, California, United States|Investigational Site 414, Orange, California, United States|Investigational Site 435, San Diego, California, United States|Investigational Site 420, Centennial, Colorado, United States|Investigational Site 444, Colorado Springs, Colorado, United States|Investigational Site 428, Aventura, Florida, United States|Investigational Site 412, Miami, Florida, United States|Investigational Site 436, Bethesda, Maryland, United States|Investigational Site 432, South Dartmouth, Massachusetts, United States|Investigational Site 426, Minneapolis, Minnesota, United States|Investigational Site 403, Plymouth, Minnesota, United States|Investigational Site 443, Columbia, Missouri, United States|Investigational Site 441, Rolla, Missouri, United States|Investigational Site 440, Saint Louis, Missouri, United States|Investigational Site 405, Bellevue, Nebraska, United States|Investigational Site 434, Skillman, New Jersey, United States|Investigational Site 408, Rochester, New York, United States|Investigational Site 418, Rockville Centre, New York, United States|Investigational Site 402, High Point, North Carolina, United States|Investigational Site 427, Raleigh, North Carolina, United States|Investigational Site 419, Cincinnati, Ohio, United States|United States 404, Cincinnati, Ohio, United States|United States 407, Edmond, Oklahoma, United States|Investigational Site 410, Oklahoma City, Oklahoma, United States|Investigational Site 424, Tulsa, Oklahoma, United States|Investigational Site 411, Pittsburgh, Pennsylvania, United States|Investigational Site 416, Spartanburg, South Carolina, United States|Investigational Site 415, Austin, Texas, United States|Investigational Site 442, Austin, Texas, United States|Investigational Site 417, Boerne, Texas, United States|Investigational Site 421, Dallas, Texas, United States|Investigational Site 430, Dallas, Texas, United States|Investigational Site 431, El Paso, Texas, United States|Investigational Site 433, Kerrville, Texas, United States|Investigational Site 422, New Braunfels, Texas, United States|Investigational Site 401, San Antonio, Texas, United States|Investigational Site 413, San Antonio, Texas, United States|Investigational Site 425, San Antonio, Texas, United States|Investigational Site 437, San Antonio, Texas, United States|Investigational Site 400, Waco, Texas, United States|Investigational Site 409, Waco, Texas, United States|Investigational Site 423, Draper, Utah, United States|Investigational Site 439, Greenfield, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02870205,0,0
8,9,NCT00073086,Evaluation and Treatment of Severe Acute Respiratory Syndrome (SARS),,Withdrawn,No Results Available,Severe Acute Respiratory Syndrome,,,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",,0.0,NIH,Observational,,040030|04-I-0030,"November 5, 2003",,"December 27, 2010","November 17, 2003",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00073086,0,0
9,10,NCT00578825,"A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome",,Unknown status,No Results Available,Severe Acute Respiratory Syndrome,Drug: Lopinavir / Ritonavir plus Ribavirin,Development of severe SARS|Adverse events|SARS-CoV Viral load|Immunological profile,"Hospital Authority, Hong Kong",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,340.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,KW/FR/04-009|HARECCTR0500028|NTWC/CREC/349/05,,,,"December 21, 2007",,"August 22, 2013","Department of Health, Hong Kong, China|Kowloon Hospital, Hong Kong, China|Prince of Wales Hospital, Hong Kong, China|Princess Margaret Hospital, Hong Kong, China|Queen Mary Hospital, Hong Kong, China|The Chinese University of Hong Kong, Hong Kong, China|The University of Hong Kong, Hong Kong, China|Tuen Mun Hospital, Hong Kong, China|United Christian Hospital, Hong Kong, China",,https://ClinicalTrials.gov/show/NCT00578825,0,0
10,11,NCT00173459,Dynamic Profiles of Cytokine/Chemokine in Severe Acute Respiratory Syndrome,,Completed,No Results Available,SARS,,,National Taiwan University Hospital,All,"20 Years and older   (Adult, Older Adult)",,,Other,Observational,Observational Model: Case Control|Time Perspective: Longitudinal|Time Perspective: Retrospective,9461700671,,,,"September 15, 2005",,"September 15, 2005",,,https://ClinicalTrials.gov/show/NCT00173459,0,0
11,12,NCT00215826,Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers,,Completed,No Results Available,Severe Acute Respiratory Syndrome,Drug: Alferon LDO,Gene expression analysis|SARS CoV Antibody|SARS-CoV infection,AIM ImmunoTech Inc.,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,10.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LDO-102,November 2004,April 2006,April 2006,"September 22, 2005",,"April 17, 2013","Princess Margaret Hospital, Lai Chi Kok, Kowloon, Hong Kong",,https://ClinicalTrials.gov/show/NCT00215826,0,0
12,13,NCT02932774,"Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)",,Completed,No Results Available,"Allergic Rhinitis|Hay Fever|SAR|Rhinitis, Allergic, Seasonal",Drug: Cetirizine|Drug: Loratadine|Other: Placebo,"Change from baseline to the Overall endpoint in the subject 24-hour reflective total symptom severity complex (TSSC) score|Change from baseline to the Overall endpoint in the subject 24-hour reflective TSSC, with and without stuffy nose score|Change from baseline to the Overall endpoint in the individual rhinoconjunctivitis symptoms (reflective and instantaneous)|Investigator evaluation of rhinoconjunctivitis symptoms|Parent/legal guardian evaluation of subject's rhinoconjunctivitis symptoms|Investigator Global Evaluations of Efficacy at Visit 4/early termination|Subject/Parent/Legal Guardian Global Evaluations at Visit 4/early termination|Parent/Legal Guardian Overall Personal Satisfaction Assessment at Visit 4/early termination|Parental Burden Questionnaire",Johnson & Johnson Consumer and Personal Products Worldwide|Pfizer,All,6 Years to 11 Years   (Child),Phase 4,683.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",A1431009,March 2001,July 2001,July 2001,"October 13, 2016",,"April 20, 2017",,,https://ClinicalTrials.gov/show/NCT02932774,0,0
13,14,NCT00150475,Contamination During Removal of Two Different Personal Protective Systems,,Completed,No Results Available,Severe Acute Respiratory Syndrome,Procedure: Powered Air purifying respirator,"The primary endpoint of this study is the presence of any detected|base clothing layer, skin, or hair contamination.|The secondary endpoints: 1) contamination episodes of any layer, and 2) protective|system donning and removal procedure violations",Queen's University|The Physicians' Services Incorporated Foundation,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,50.0,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single|Primary Purpose: Educational/Counseling/Training,PSI 04-58,January 2005,,May 2005,"September 8, 2005",,"September 8, 2005","Kingston General Hospital, Kingston, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00150475,0,0
14,15,NCT02497885,Seroprevalence of MERS-CoV IgG in Healthcare Workers,,Completed,No Results Available,Coronavirus Infections,,IgG(+),Ewha Womans University Mokdong Hospital,All,"18 Years and older   (Adult, Older Adult)",,737.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,KMSG_HCW_IgG,August 2015,October 2015,October 2015,"July 15, 2015",,"October 30, 2015","Ewha womans university mokdong hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02497885,0,0
15,16,NCT03301090,"A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051",,Completed,No Results Available,Corona Virus Infection,Other: Placebo|Biological: REGN3048|Biological: REGN3051,"Changes from baseline in abbreviated physical examination|Changes from baseline in clinical safety laboratory values|Changes from baseline in Electrocardiogram (ECG) parameters|Changes from baseline in symptom-directed physical examination|Changes from baseline in vital signs|The incidence of Adverse Events|The incidence of treatment-emergent Serious Adverse Events|The severity of Adverse Events assessed by toxicity grading criteria|The severity of treatment-emergent Serious Adverse Events assessed by toxicity grading criteria|The type of treatment-emergent Serious Adverse Events|AUC for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|AUC for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|AUC(0-infinity) for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|AUC(0-infinity) for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|CL for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|CL for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|CMAX for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|CMAX for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|K(e) for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|K(e) for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|t(1/2) for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|t(1/2) for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|The change from baseline of antibodies against REGN3048 and REGN3051 (anti-drug antibodies, ADA), as measured in serum using validated bridging assays|TMAX for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|TMAX for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|V(ss) for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|V(ss) for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)",National Institute of Allergy and Infectious Diseases (NIAID),All,18 Years to 45 Years   (Adult),Phase 1,48.0,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",15-0109|HHSN272201500005I,"February 12, 2018","January 19, 2019","January 19, 2019","October 4, 2017",,"February 1, 2019","WCCT Global Cypress Clinical Pharmacology Unit, Cypress, California, United States",,https://ClinicalTrials.gov/show/NCT03301090,0,0
16,17,NCT00172263,The Interaction Between Severe Acute Respiratory Distress Syndrome Viral Proteins and Monocytes,,Withdrawn,No Results Available,Severe Acute Respiratory Syndrome,Procedure: blood sampling,,National Taiwan University Hospital,All,"Child, Adult, Older Adult",Not Applicable,0.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),9261701054,,,,"September 15, 2005",,"December 10, 2012","Li-Chieh Wang, MD, Taipei, Taiwan, China",,https://ClinicalTrials.gov/show/NCT00172263,0,0
17,18,NCT01936363,Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer,,Completed,Has Results,Ovarian Cancer,Drug: Pimasertib once daily|Drug: Pimasertib placebo|Drug: SAR245409 placebo|Drug: SAR245409|Drug: Pimasertib twice daily,"Objective Tumor Response|Progression-Free Survival|Percentage of Participants With Disease Control|Overall Survival|Health Related Quality of Life (HrQoL) Assessed Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30)|Health Related Quality of Life (HrQoL) Assessed Using European Organization for Research and Treatment of Cancer (EORTC) Ovarian-Specific Module Quality of Life Questionnaire Ovarian Cancer Module (QLQ-OV28)|Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation of Treatment and Death|Maximum Plasma Concentration (Cmax) After Dose of Pimasertib and SAR245409|Area Under the Curve (AUC) After Dose of Pimasertib and SAR245409|Molecular Alterations in MAPK and/or PI3K Signaling Pathway Components/Modulators in Tumor Tissue and Blood",EMD Serono|Sanofi,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,65.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EMR 200066_012|2013-000902-40,"September 30, 2013","May 31, 2015","November 30, 2017","September 6, 2013","April 7, 2017","December 12, 2018","Research site, Augusta, Georgia, United States|Research site, Chicago, Illinois, United States|Research site, Indianapolis, Indiana, United States|Research site, Silver Spring, Maryland, United States|Research site, Boston, Massachusetts, United States|Research site, Boston, Massachusetts, United States|Research site, Ann Arbor, Michigan, United States|Research site, Detroit, Michigan, United States|Research site, Kansas City, Missouri, United States|Research site, Saint Louis, Missouri, United States|Research site, Kalispell, Montana, United States|Research site, New York, New York, United States|Research site, Cincinnati, Ohio, United States|Research site, Columbus, Ohio, United States|Research site, Middletown, Ohio, United States|Research site, Nashville, Tennessee, United States|Research site, Houston, Texas, United States|Research site, Northmead, New South Wales, Australia|Research site, Greenslopes, Queensland, Australia|Research site, Subiaco, Western Australia, Australia|Research site, Kortrijk, Belgium|Research site, Leuven, Belgium|Research site, Hamilton, Ontario, Canada|Research site, Toronto, Ontario, Canada|Research site, Montreal, Quebec, Canada|Research site, Montreal, Quebec, Canada|Research site, Quebec, Canada|Research site, Bordeaux Cedex, Gironde, France|Research site, Chorzow, Poland|Research site, Palma Mallorca, Baleares, Spain|Research site, Madrid, Spain|Research site, Madrid, Spain|Research site, Sevilla, Spain|Research site, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT01936363,0,0
18,19,NCT00807053,Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602),,Completed,No Results Available,"Rhinitis, Allergic, Seasonal",Drug: Ciclesonide HFA|Drug: Placebo,Average of AM and PM patient-reported reflective Total Nasal Symptom Score (TNSS) over the first two weeks of treatment|Average of AM and PM patient-reported instantaneous TNSS over the first two weeks of treatment|Physician-assessed total nasal symptoms score (PNSS) over the treatment period|Rhinoconjunctivitis Quality of Life Questionaire (RQLQ) over the treatment period in patients (adolescents and adults) with impaired quality of life at Baseline defined as a RQLQ score of greater than 3.0,AstraZeneca,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 2,480.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",BY9010/M1-602,April 2007,June 2007,July 2007,"December 11, 2008",,"December 5, 2016","Altana/Nycomed, Mission Viejo, California, United States|Altana/Nycomed, Orange, California, United States|Altana/Nycomed, San Diego, California, United States|Altana/Nycomed, Colorado Springs, Colorado, United States|Altana/Nycomed, Denver, Colorado, United States|Altana/Nycomed, Gainsville, Georgia, United States|Altana/Nycomed, Savannah, Georgia, United States|Altana/Nycomed, Stockbridge, Georgia, United States|Altana/Nycomed, Indianapolis, Indiana, United States|Altana/Nycomed, Overland Park, Kansas, United States|Altana/Nycomed, Bethesda, Maryland, United States|Altana/Nycomed, Minneapolis, Minnesota, United States|Altana/Nycomed, St. Louis, Missouri, United States|Altana/Nycomed, Lincoln, Nebraska, United States|Altana/Nycomed, Papillion, Nebraska, United States|Altana/Nycomed, Skillman, New Jersey, United States|Altana/Nycomed, West Brick, New Jersey, United States|Altana/Nycomed, Raleigh, North Carolina, United States|Altana/Nycomed, Ashland, Oregon, United States|Altana/Nycomed, Medford, Oregon, United States|Altana/Nycomed, Portland, Oregon, United States|Altana/Nycomed, Blue Bell, Pennsylvania, United States|Altana/Nycomed, Pittsburgh, Pennsylvania, United States|Altana/Nycomed, Upland, Pennsylvania, United States|Altana/Nycomed, Charleston, South Carolina, United States|Altana/Nycomed, Austin, Texas, United States|Altana/Nycomed, New Braunfels, Texas, United States|Altana/Nycomed, San Antonio, Texas, United States|Altana/Nycomed, Draper, Utah, United States|Altana/Nycomed, Burke, Virginia, United States|Altana/Nycomed, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00807053,0,0
19,20,NCT03331380,Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System,,Recruiting,No Results Available,CAD,Device: MRI scan x 1 Healthy Volunteer|Device: MRI scan x 2 Healthy Volunteer|Device: MRI scan x 2 - CAD patients|Device: MRI scan x 2- non CAD patients,Technical feasibility and Non- inferiority of the above measurements and examinations obtained using low SAR CMR versus commercial CMR in healthy volunteers and in patients with heart disease|Numerous exploratory secondary endpoints are sought around the listed measurements across MRI systems and disease states,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,1600.0,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,180011|18-H-0011,"January 5, 2018","May 31, 2022","May 31, 2022","November 6, 2017",,"January 9, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03331380,0,0
20,21,NCT03705169,Pharmacokinetics of SAR441236,,Recruiting,No Results Available,HIV-1-infection,Biological: SAR441236|Biological: Placebo|Drug: Antiretroviral treatment,"Occurrence of a Grade 3 or higher adverse event (AE) that is related to study treatment (as judged by the core safety team, blinded to active/placebo treatment in Arm A) any time from study treatment administration through the entire follow-up|Occurrence of a Grade 3 or higher AE that is related to study treatment (as judged by the core safety team, blinded to active/placebo treatment in Arm A) any time from study treatment administration through the entire follow-up|AUC12wk of SAR441236|Change in plasma HIV-1 RNA (log10 copies/mL) from baseline (defined as the last measurement taken prior to the treatment initiation) to Day 7 of monotherapy for treatment-naïve, viremic participants with HIV (Arm B cohorts)|Change in plasma HIV-1 RNA (copies/mL) from baseline and post infusion for treatment-naïve, viremic participants with HIV (Arm B cohorts)|Change in plasma HIV-1 RNA (log10 copies/mL) from baseline (defined as the last measurement taken prior to treatment initiation) to Day 14 and Day 28 of monotherapy for Arm B cohorts|Maximum reduction of plasma HIV-1 RNA during 28 days of monotherapy for treatment-naïve, viremic participants with HIV (Arm B cohorts)|Attributions of anti-SAR441236 antibodies|Change in CD4+ T cell counts (cells/mm^3) from baseline to week 12 following single dose of SAR441236 for all cohorts|Change in CD4+ T cell counts (cells/mm^3) from baseline to week 12 following each infusion for Cohort 4|Maximum concentration of SAR441236 after infusion for Cohorts 1-3 and Arm B cohorts|Trough concentration of SAR441236 after infusion for Cohorts 1-3 and Arm B cohorts|Half life of SAR441236 after infusion for Cohorts 1-3 and Arm B cohorts|Time to half life of SAR441236 after infusion for Cohorts 1-3 and Arm B cohorts|Clearance of SAR441236 after infusion for Cohorts 1-3 and Arm B cohorts|Distribution volume of SAR441236 after infusion for Cohorts 1-3 and Arm B cohorts|Maximum concentration of SAR441236 after each infusion for Cohort 4|Trough concentration of SAR441236 after each infusion for Cohort 4|Half life of SAR441236 after each infusion for Cohort 4|Time to half life of SAR441236 after each infusion for Cohort 4|Clearance of SAR441236 after each infusion for Cohort 4|Distribution volume of SAR441236 after each infusion for Cohort 4|Establish concentration (or dose)-response relationship between SAR441236 exposure and changes in plasma HIV-1 RNA from entry baseline to week 4 (or viral load nadir) for Arm B cohorts",National Institute of Allergy and Infectious Diseases (NIAID)|Sanofi,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,60.0,NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5377|38508|TDU15867,"April 22, 2019","June 30, 2021","June 30, 2021","October 15, 2018",,"January 14, 2020","Alabama CRS, Birmingham, Alabama, United States|UCLA CARE Center CRS, Los Angeles, California, United States|UCSD Antiviral Research Center CRS, San Diego, California, United States|Ucsf Hiv/Aids Crs, San Francisco, California, United States|Harbor-UCLA CRS, Torrance, California, United States|University of Colorado Hospital CRS, Aurora, Colorado, United States|The Ponce de Leon Center CRS, Atlanta, Georgia, United States|Northwestern University CRS, Chicago, Illinois, United States|Rush University CRS, Chicago, Illinois, United States|Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States|Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS, Boston, Massachusetts, United States|Washington University Therapeutics (WT) CRS, Saint Louis, Missouri, United States|New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States|Weill Cornell Chelsea CRS, New York, New York, United States|Columbia P&S CRS, New York, New York, United States|Weill Cornell Uptown CRS, New York, New York, United States|University of Rochester Adult HIV Therapeutic Strategies Network CRS, Rochester, New York, United States|Chapel Hill CRS, Chapel Hill, North Carolina, United States|Cincinnati Clinical Research Site, Cincinnati, Ohio, United States|Case Clinical Research Site, Cleveland, Ohio, United States|Ohio State University CRS, Columbus, Ohio, United States|Penn Therapeutics, CRS, Philadelphia, Pennsylvania, United States|University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States|The Miriam Hospital Clinical Research Site (TMH CRS) CRS, Providence, Rhode Island, United States|Vanderbilt Therapeutics (VT) CRS, Nashville, Tennessee, United States|University of Washington AIDS CRS, Seattle, Washington, United States|Puerto Rico AIDS Clinical Trials Unit CRS, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT03705169,0,0
21,22,NCT00173576,Clinical Study of SARS in Children,,Completed,No Results Available,Epidemiology,,,"National Taiwan University Hospital|National Science Council, Taiwan",All,"1 Month to 18 Years   (Child, Adult)",,800.0,Other,Observational,Primary Purpose: Screening|Time Perspective: Cross-Sectional|Time Perspective: Retrospective/Prospective,9461700732|NSC92-2751-B-002-013-Y,April 2003,,March 2005,"September 15, 2005",,"October 27, 2005",,,https://ClinicalTrials.gov/show/NCT00173576,0,0
22,23,NCT02635243,"A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced Hypoglycemia",,Withdrawn,No Results Available,Type 1 Diabetes Mellitus,Drug: SAR438544|Drug: r-glucagon|Drug: insulin,Time to reach a smoothed blood glucose of 70 mg/dL after initial administration of investigational medicinal product|Assessment of PD parameter: continuous monitoring of blood glucose levels over a period of 6 hours post-dose|Assessment of PD parameter: area under plasma concentration of the BG-time curve between IMP dosing and time t (BG-AUC0-t)|Assessment of PD parameter: BG-maximum concentration (BG-Cmax)|Assessment of PD parameter: BG-time to Cmax (BG-tmax)|Assessment of PK parameter (recombinant glucagon and SAR438544): Cmax|Assessment of PK parameter (recombinant glucagon and SAR438544): tmax|Assessment of PK parameter (recombinant glucagon and SAR438544): tlast|Assessment of PK parameter (recombinant glucagon and SAR438544): terminal half-life|Assessment of PK parameter (recombinant glucagon and SAR438544): area under curve from zero time until the last measurable concentration (AUClast)|Assessment of PK parameter (recombinant glucagon and SAR438544): AUC|Assessment of PK parameter (recombinant glucagon and SAR438544): partial AUCs (AUC0-t)|Number of patients with adverse events|Time to reach a smoothed blood glucose of 90 mg/dL after initial administration of investigational medicinal product,Sanofi,All,18 Years to 60 Years   (Adult),Phase 1,0.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Basic Science,PDY14452|U1111-1172-1152,April 2016,November 2016,November 2016,"December 18, 2015",,"September 2, 2016",,,https://ClinicalTrials.gov/show/NCT02635243,0,1
23,24,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,,Completed,No Results Available,Relapsing Multiple Sclerosis,Drug: SAR442168|Drug: Placebo|Drug: Locally approved intravenous contrast medium for contrast enhanced MRI,Number of new Gd-enhancing T1 hyperintense lesions|Number of new or enlarging T2 lesions|Total number of Gd-enhancing T1 hyperintense lesions|Number of participants experiencing adverse events|Percentage of participants experiencing adverse events,Sanofi,All,18 Years to 55 Years   (Adult),Phase 2,128.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DRI15928|2018-003927-12|U1111-1220-0572,"March 29, 2019","January 2, 2020","January 2, 2020","March 26, 2019",,"January 13, 2020","Investigational Site Number 8400005, Cullman, Alabama, United States|Investigational Site Number 8400002, Maitland, Florida, United States|Investigational Site Number 8400004, Sunrise, Florida, United States|Investigational Site Number 8400009, Tampa, Florida, United States|Investigational Site Number 8400007, Savannah, Georgia, United States|Investigational Site Number 8400001, Northbrook, Illinois, United States|Investigational Site Number 8400008, Dayton, Ohio, United States|Investigational Site Number 8400006, Westerville, Ohio, United States|Investigational Site Number 8400003, Knoxville, Tennessee, United States|Investigational Site Number 1240002, Gatineau, Canada|Investigational Site Number 1240001, Greenfield Park, Canada|Investigational Site Number 1240003, Vancouver, Canada|Investigational Site Number 2030007, Brno, Czechia|Investigational Site Number 2030004, Hradec Kralove, Czechia|Investigational Site Number 2030003, Jihlava, Czechia|Investigational Site Number 2030005, Ostrava - Poruba, Czechia|Investigational Site Number 2030006, Pardubice, Czechia|Investigational Site Number 2030001, Praha 2, Czechia|Investigational Site Number 2030002, Praha 5 - Motol, Czechia|Investigational Site Number 2330001, Tallinn, Estonia|Investigational Site Number 2500004, Nancy Cedex, France|Investigational Site Number 2500001, Nantes Cedex 1, France|Investigational Site Number 2500002, Strasbourg Cedex, France|Investigational Site Number 2500003, Toulouse Cedex 9, France|Investigational Site Number 5280001, Amsterdam, Netherlands|Investigational Site Number 5280002, Sittard-Geleen, Netherlands|Investigational Site Number 6430006, Kazan, Russian Federation|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation|Investigational Site Number 6430001, Saint-Petersburg, Russian Federation|Investigational Site Number 6430005, St-Petersburg, Russian Federation|Investigational Site Number 6430004, St-Petersburg, Russian Federation|Investigational Site Number 6430007, Tyumen, Russian Federation|Investigational Site Number 7030001, Bratislava, Slovakia|Investigational Site Number 7030002, Martin, Slovakia|Investigational Site Number 7240006, Barakaldo, Spain|Investigational Site Number 7240002, Barcelona, Spain|Investigational Site Number 7240001, Madrid, Spain|Investigational Site Number 7240004, Murcia, Spain|Investigational Site Number 7240005, Salt, Spain|Investigational Site Number 7240003, Sevilla, Spain|Investigational Site Number 8040002, Chernivtsi, Ukraine|Investigational Site Number 8040005, Dnipro, Ukraine|Investigational Site Number 8040001, Lviv, Ukraine|Investigational Site Number 8040006, Lviv, Ukraine|Investigational Site Number 8040009, Odesa, Ukraine|Investigational Site Number 8040003, Vinnytsya, Ukraine|Investigational Site Number 8040007, Zhytomyr, Ukraine",,https://ClinicalTrials.gov/show/NCT03889639,0,0
24,25,NCT02575781,A Study of SAR428926 in Patients With Advanced Solid Tumors,,Completed,No Results Available,Neoplasm Malignant,Drug: SAR428926,Number of patients with dose limiting adverse events (Escalation cohort)|Number of patients with corneal adverse events impacting study treatment (Escalation cohort)|Assessment of overall response rate using standard imaging and RECIST v1.1 criteria (Expansion cohort)|Number of treatment emergent adverse events|Assessment of PK parameter: maximum concentration (Cmax)|Assessment of PK parameter: time to reach maximum concentration (tmax)|Assessment of PK parameter: trough plasma concentration (Ctrough)|Assessment of PK parameter: area under the plasma concentration curve versus time curve between 1 and 14 days (AUC0-14 day)|Assessment of PK parameter: mean systemic clearance (CL)|Assessment of PK parameter: clearance at steady state (CLss)|Assessment of PK parameter: accumulation ratio on AUC0-14|Assessment of PK parameter: accumulation ratio on Cmax|Preliminary tumor response by RECIST v1.1 (Escalation)|Number of corneal events according to the presence or not of preventive measures,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 1,34.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TED14147|2015-001441-92|U1111-1168-4706,"October 5, 2015",June 2018,June 2018,"October 15, 2015",,"August 22, 2018","Investigational Site Number 2080001, København Ø, Denmark|Investigational Site Number 2500001, Villejuif Cedex, France|Investigational Site Number 7240001, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT02575781,0,0
25,26,NCT02283775,"SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients",PomdeSAR,"Active, not recruiting",No Results Available,Plasma Cell Myeloma,Drug: Isatuximab SAR650984|Drug: Pomalidomide|Drug: Dexamethasone,Dose Limiting Toxicities (DLTs)|Number of patients with adverse events and clinically significant changes in laboratory tests and vital signs according to the National Cancer Institute - Common Toxicity Criteria (NCI-CTC) version 4.03 grade scaling|Incidence of grade ≥3 IARs according to the NCI-CTC version 4.03 grade scaling|Overall response rate|Pharmacokinetics: Partial area under the serum concentration time curve (AUC)|Pharmacokinetics: maximum observed concentration (Cmax)|Immune response: levels of human anti-human antibodies (ADA)|Duration of response - Time|Clinical Benefit rate|Infusion duration|Safety of isatuximab administration from fixed volume|Relationship between clinical effect and CD38 receptor density,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 1,89.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TCD14079|U1111-1155-7484,"May 15, 2015",November 2020,November 2020,"November 5, 2014",,"March 28, 2019","Investigational Site Number 840001, Scottsdale, Arizona, United States|Investigational Site Number 840006, Duarte, California, United States|Investigational Site Number 840018, New Haven, Connecticut, United States|Investigational Site Number 840011, Decatur, Illinois, United States|Investigational Site Number 840004, Boston, Massachusetts, United States|Investigational Site Number 840104, Boston, Massachusetts, United States|Investigational Site Number 840010, Chapel Hill, North Carolina, United States|Investigational Site Number 840003, Charlotte, North Carolina, United States|Investigational Site Number 840014, Canton, Ohio, United States|Investigational Site Number 840016, Charleston, South Carolina, United States|Investigational Site Number 840015, Salt Lake City, Utah, United States|Investigational Site Number 840005, Seattle, Washington, United States|Investigational Site Number 840017, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02283775,0,0
26,27,NCT01440179,SAR3419 in Acute Lymphoblastic Leukemia,MYRALL,Terminated,No Results Available,Acute Lymphocytic Leukaemia,Drug: SAR3419,Number of participants achieving an Objective Response Rate|Number of participants with Adverse Events|Assessment of PK parameter - maximum concentration (Cmax)|Assessment of PK parameter - area under curve (AUC)|Assessment of PK parameter - half-life (T1/2)|Assessment of PK parameter - clearance|Assessment of PK parameter - volume in steady state (Vss)|Assessment of minimal residual disease (MRD),Sanofi,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 2,100.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EFC11603|U1111-1118-0642|2012-002961-36,October 2011,May 2014,May 2014,"September 26, 2011",,"August 27, 2014","Investigational Site Number 840006, Denver, Colorado, United States|Investigational Site Number 840003, Nashville, Tennessee, United States|Investigational Site Number 840001, Houston, Texas, United States|Investigational Site Number 840002, San Antonio, Texas, United States|Investigational Site Number 840004, Milwaukee, Wisconsin, United States|Investigational Site Number 250006, Amiens, France|Investigational Site Number 250001, Paris Cedex 10, France|Investigational Site Number 250002, Pessac, France|Investigational Site Number 250008, Pierre Benite, France|Investigational Site Number 250004, Rennes, France|Investigational Site Number 250005, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT01440179,0,0
27,28,NCT02332850,SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma,,Unknown status,No Results Available,Multiple Myeloma,Drug: SAR650984|Drug: Carfilzomib,Adverse Events|Maximum Tolerated Dose|Immunogenicity of SAR650984|Overall response rate|Clinical benefit response|Overall survival (OS)|Progression Free Survival (PFS)|Time To Progression (TTP)|Duration of Response (DOR)|CD38 receptor density levels|Receptor density levels|Receptor occupancy,"University of California, San Francisco",All,"up to 18 Years   (Child, Adult)",Phase 1,42.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,139511,December 2014,December 2018,December 2019,"January 7, 2015",,"September 18, 2017","UCSF, 400 Parnassus Ave, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT02332850,0,0
28,29,NCT02855268,Study of SAR339375 in Patients With Alport Syndrome,HERA,Recruiting,No Results Available,Alport's Syndrome,Drug: SAR339375|Drug: Placebo,Number of participants with adverse events|Annualized change in estimated glomerular filtration rate eGFR from baseline|Pharmacokinetics (PK) : Maximum concentration in plasma (Cmax)|Pharmacokinetics (PK) : Trough plasma concentration (Ctrough)|Number of participants with anti-drug antibodies (ADAs)|Number of participant with adverse events associated to ADAs|Percent change in eGFR values|Proportion of subjects who reach end staged renal disease (ESRD),"Genzyme, a Sanofi Company|Sanofi",All,18 Years to 55 Years   (Adult),Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",ACT16248|2019-004394-10|U1111-1223-4466|RG012-03,"November 2, 2019",April 2023,April 2023,"August 4, 2016",,"January 31, 2020","Investigational Site Number 8400001, Cleveland, Ohio, United States|Investigational Site Number 0360003, Herston, Australia",,https://ClinicalTrials.gov/show/NCT02855268,0,0
29,30,NCT03324113,Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors,,Recruiting,No Results Available,Neoplasm Malignant,Biological: SAR408701|Drug: dexamethasone|Drug: naphazoline|Drug: diphenhydramine,IMP-related dose limiting toxicities (DLT)|Treatment emergent adverse events|Maximum observed concentration (Cmax) of SAR408701|Cmax of DM4 and Me-DM4|Time to reach maximum concentration (Tmax) of SAR408701|Tmax of DM4 and Me-DM4|Area under the concentration-time curve (AUC) of SAR408701|AUC of DM4 and Me-DM4|Assessment of PDy effect|Assessment of anti-tumor activity|Detection of anti-SAR408701 antibody,Sanofi,All,"20 Years and older   (Adult, Older Adult)",Phase 1,63.0,Industry,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TCD15054|U1111-1191-5464,"October 17, 2017",August 2021,August 2021,"October 27, 2017",,"July 5, 2019","Investigational Site Number 3920003, Kashiwa-Shi, Japan|Investigational Site Number 3920002, Nagoya-Shi, Japan|Investigational Site Number 3920001, Sunto-Gun, Japan",,https://ClinicalTrials.gov/show/NCT03324113,0,0
30,31,NCT03996291,Long Term Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis,,Recruiting,No Results Available,Relapsing Multiple Sclerosis,Drug: SAR442168,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants with Potentially Clinically Significant Abnormalities|Number of new gadolinium (Gd)-enhancing T1 hyperintense lesions|Number of new or enlarging T2 lesions|Total number of Gd-enhancing T1-hyperintense lesions|Number of participants wih relapse (Annualized Relapse rate)|Change in Expanded Disability Status Scale (EDSS) from baseline over time,Sanofi,All,18 Years to 55 Years   (Adult),Phase 2,105.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LTS16004|2018-004731-76|U1111-1223-4256,"September 23, 2019",January 2025,January 2025,"June 24, 2019",,"January 29, 2020","Investigational Site Number 8400005, Cullman, Alabama, United States|Investigational Site Number 8400002, Maitland, Florida, United States|Investigational Site Number 8400009, Tampa, Florida, United States|Investigational Site Number 8400007, Savannah, Georgia, United States|Investigational Site Number 8400001, Northbrook, Illinois, United States|Investigational Site Number 8400008, Dayton, Ohio, United States|Investigational Site Number 8400006, Westerville, Ohio, United States|Investigational Site Number 8400003, Knoxville, Tennessee, United States|Investigational Site Number 1240001, Greenfield Park, Canada|Investigational Site Number 1240003, Vancouver, Canada|Investigational Site Number 2030007, Brno, Czechia|Investigational Site Number 2030004, Hradec Kralove, Czechia|Investigational Site Number 2030003, Jihlava, Czechia|Investigational Site Number 2030005, Ostrava - Poruba, Czechia|Investigational Site Number 2030006, Pardubice, Czechia|Investigational Site Number 2030001, Praha 2, Czechia|Investigational Site Number 2030002, Praha 5 - Motol, Czechia|Investigational Site Number 2330001, Tallinn, Estonia|Investigational Site Number 2500004, Nancy Cedex, France|Investigational Site Number 5280001, Amsterdam, Netherlands|Investigational Site Number 6430001, Saint-Petersburg, Russian Federation|Investigational Site Number 7240002, Barcelona, Spain|Investigational Site Number 7240001, Madrid, Spain|Investigational Site Number 7240004, Murcia, Spain|Investigational Site Number 7240005, Salt, Spain|Investigational Site Number 7240003, Sevilla, Spain",,https://ClinicalTrials.gov/show/NCT03996291,0,0
31,32,NCT02187848,Evaluation of SAR408701 in Patients With Advanced Solid Tumors,,Recruiting,No Results Available,Neoplasm Malignant,Drug: SAR408701,Number of dose limiting adverse events (every 2 week cycle)|Assessment of overall response rate using standard imaging and RECIST 1.1 criteria|Number of dose limiting adverse events (every 3 week cycle)|Number of treatment emergent adverse events|Maximum concentration (Cmax)|Time to reach maximum concentration (tmax)|Trough plasma concentrations (Ctrough)|Area under the plasma concentration versus time curve between 0 and 14 days (AUC0-14day) for Q2W or between 0 and 21 days (AUC-21 day) for Q3W|Mean systemic clearance (CL)|Clearance at steady state (CLss)|Accumulation ratio (Rac) on AUC0-14day and Cmax|Detection of the development of anti-SAR408701 antibody|Duration of response|Time to Progression,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,337.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TED13751|2014-001130-29,"July 23, 2014",June 2021,June 2021,"July 11, 2014",,"January 10, 2020","Investigational Site Number 840006, Bakersfield, California, United States|Investigational Site Number 840003, Santa Monica, California, United States|Investigational Site Number 840002, New Haven, Connecticut, United States|Investigational Site Number 840105, Boston, Massachusetts, United States|Investigational Site Number 840005, Boston, Massachusetts, United States|Investigational Site Number 840001, Hackensack, New Jersey, United States|Investigational Site Number 840004, Milwaukee, Wisconsin, United States|Investigational Site Number 124001, Toronto, Canada|Investigational Site Number 250003, Bordeaux Cedex, France|Investigational Site Number 250006, Dijon, France|Investigational Site Number 250004, Marseille Cedex 5, France|Investigational Site Number 250007, Rennes, France|Investigational Site Number 250005, Saint Mande, France|Investigational Site Number 250002, Toulouse Cedex 9, France|Investigational Site Number 250001, Villejuif Cedex, France|Investigational Site Number 410002, Seoul, Korea, Republic of|Investigational Site Number 410005, Seoul, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 410001, Seoul, Korea, Republic of|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724007, Madrid, Spain|Investigational Site Number 724004, Madrid, Spain|Investigational Site Number 724006, Madrid, Spain|Investigational Site Number 724003, Madrid, Spain|Investigational Site Number 724002, Majadahonda, Spain",,https://ClinicalTrials.gov/show/NCT02187848,0,0
32,33,NCT04154956,"SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients",CARMEN-LC03,Recruiting,No Results Available,Non-small Cell Lung Cancer Metastatic,Drug: SAR408701|Drug: Docetaxel,Progression free survival (PFS)|Overall Survival (OS)|Objective response rate (ORR)|Health related quality of life (HRQOL) - disease related symptoms|Health related quality of life (HRQOL) - physical function|Health related quality of life (HRQOL) - role function|Number of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)|Duration of response (DOR),Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,554.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EFC15858|2019-001273-81|U1111-1233-0781,"November 26, 2019",March 2024,March 2024,"November 7, 2019",,"January 28, 2020","Investigational Site Number 8400007, Bakersfield, California, United States|Investigational Site Number 0360002, Blacktown, Australia|Investigational Site Number 0360003, Waratah, Australia|Investigational Site Number 0360001, Woolloongabba, Australia|Investigational Site Number 1240004, Montreal, Canada|Investigational Site Number 3920001, Hirakata-Shi, Japan|Investigational Site Number 6430003, Saint -Petersburg, Russian Federation|Investigational Site Number 7920004, Ankara, Turkey|Investigational Site Number 7920003, Edirne, Turkey|Investigational Site Number 7920005, Istanbul, Turkey|Investigational Site Number 7920001, Istanbul, Turkey|Investigational Site Number 7920009, Malatya, Turkey",,https://ClinicalTrials.gov/show/NCT04154956,0,0
33,34,NCT04191382,"Study of SAR439859 Versus Letrozole in ER Positive, HER2 Negative Pre-operative Post-menopausal Primary Breast Cancer",,Recruiting,No Results Available,Breast Cancer,Drug: SAR439859|Drug: letrozole,Ki67|Ki67≥50%|ER Expression|Adverse Events (AEs)/Serious Adverse Events (SAEs)|Clinical Laboratory Test Abnormalities,Sanofi,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,126.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,ACT16106|2019-002015-26|U1111-1228-9473,"November 20, 2019","October 27, 2020","November 20, 2020","December 9, 2019",,"December 9, 2019","Investigational Site Number 8400018, Fort Wayne, Indiana, United States|Investigational Site Number 8400007, Hato Rey, Puerto Rico",,https://ClinicalTrials.gov/show/NCT04191382,0,0
34,35,NCT01749969,"SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients",,"Active, not recruiting",No Results Available,Plasma Cell Myeloma,Drug: isatuximab SAR650984|Drug: lenalidomide|Drug: dexamethasone,Number of patients with adverse events when treated with SAR650984 (isatuximab) in combination with LD|Preliminary assessment of overall response rate|Preliminary assessment of progression-free survival (PFS)|Assessment of PK parameters - maximum concentration (Cmax)|Assessment of PK parameters - time to reach Cmax (Tmax)|Assessment of PK parameters - concentration observed at end of infusion (Ceoi)|Assessment of PK parameters - area under the plasma concentration versus time curve over the dosing interval (AUCtau)|Assessment of PK parameters - plasma concentration observed just before treatment administration during repeated dosing (Ctrough)|Number of CD38 receptors occupied by SAR650984 (isatuximab)|CD38 receptor density|Immunogenicity: Number of anti-SAR650984 (isatuximab) antibodies in response to SAR650984 (isatuximab),Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 1,60.0,Industry,Interventional,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TCD11863|U1111-1119-3107,"February 6, 2013",June 2020,June 2020,"December 17, 2012",,"November 20, 2019","Investigational Site Number 840004, San Francisco, California, United States|Investigational Site Number 840001, Tampa, Florida, United States|Investigational Site Number 840002, Saint Louis, Missouri, United States|Investigational Site Number 840005, New York, New York, United States|Investigational Site Number 840003, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01749969,0,0
35,36,NCT01636479,Phase 1 Safety Testing of SAR405838,,Completed,No Results Available,Neoplasm Malignant,Drug: SAR405838,"SAR405838 Maximum tolerated dose (MTD)|In MTD cohort, clinical benefit|Adverse events (eg, number of patients experiencing AEs)|PK parameters (Cmax, Tmax, AUC)|Biomarkers|Clinical response|Drug administration compliance",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 1,77.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TED12318|2012-000733-39|U1111-1127-2911,"July 13, 2012","March 5, 2018","March 5, 2018","July 10, 2012",,"May 17, 2018","Investigational Site Number 840101, Boston, Massachusetts, United States|Investigational Site Number 840001, Boston, Massachusetts, United States|Investigational Site Number 840002, New York, New York, United States|Investigational Site Number 250001, Villejuif, France|Investigational Site Number 528001, Amsterdam, Netherlands|Investigational Site Number 528003, Rotterdam, Netherlands|Investigational Site Number 528002, Utrecht, Netherlands",,https://ClinicalTrials.gov/show/NCT01636479,0,0
36,37,NCT04171310,Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male Subjects,,Completed,No Results Available,Multiple Sclerosis,Drug: SAR442168,Percentage of radioactive dose excreted in urine and feces|Number of subjects with Adverse events|Blood/plasma radioactivity ratio|Plasma SAR442168 /radioactivity ratio,Sanofi,Male,"30 Years to 65 Years   (Adult, Older Adult)",Phase 1,6.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BEX16018|2019-001069-33|U1111-1223-4541,"November 13, 2019","December 30, 2019","December 30, 2019","November 20, 2019",,"January 21, 2020","Investigational Site Number 8260001, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT04171310,0,0
37,38,NCT03436498,Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients,,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Insulin aspart SAR341402|Drug: Insulin aspart,"Infusion set occlusions|Unexplained hyperglycemia|Intervals for infusion set changes|Number of patients with insulin pump alarms for ""non-delivery""|Patient observation of infusion set occlusion|Adverse events and serious adverse events|Number of patients with hypoglycemic events",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 1,45.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PDY15083|U1111-1200-1241,"May 10, 2018","October 6, 2018","October 6, 2018","February 19, 2018",,"December 7, 2018","Investigational Site Number 8400001, Little Rock, Arkansas, United States|Investigational Site Number 8400002, Denver, Colorado, United States|Investigational Site Number 8400003, West Des Moines, Iowa, United States",,https://ClinicalTrials.gov/show/NCT03436498,0,1
38,39,NCT01836705,Effect of SAR302503 on ECG Activity in Patients With Solid Tumors,,Completed,No Results Available,Neoplasm Malignant,Drug: SAR302503 (TG101348)|Drug: Placebo SAR302503|Drug: Panolosetron,"QTc Friderica (QTcF) parameter|Electrocardiographic parameters (Heart Rate)|Electrocardiographic parameters (QT)|Electrocardiographic parameters (QTcBazett)|Electrocardiographic parameters (QTcN)|Electrocardiographic parameters (PR interval)|Electrocardiographic parameters (QRS interval)|Anti-tumor activity|Number of participants with Adverse Events|Pharmacokinetic parameter: Cmax, AUC0-24, Tmax, Tmax, Ctrough",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 1,60.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,TES13519|2012-005642-38|U1111-1115-7323,May 2013,November 2013,May 2014,"April 22, 2013",,"June 4, 2014","Investigational Site Number 840003, Los Angeles, California, United States|Investigational Site Number 840007, Augusta, Georgia, United States|Investigational Site Number 840002, Detroit, Michigan, United States|Investigational Site Number 840001, St Louis, Missouri, United States|Investigational Site Number 840004, Cincinnati, Ohio, United States|Investigational Site Number 840005, Philadelphia, Pennsylvania, United States|Investigational Site Number 840006, San Antonio, Texas, United States|Investigational Site Number 840008, San Antonio, Texas, United States|Investigational Site Number 056001, Bruxelles, Belgium|Investigational Site Number 056002, Gent, Belgium",,https://ClinicalTrials.gov/show/NCT01836705,0,0
39,40,NCT02921971,Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis,,Completed,No Results Available,Systemic Sclerosis,Drug: SAR156597 (ACT14604)|Drug: Placebo,"Change from baseline in mRSS|Change from baseline in Health Assessment Questionnaire Disability Index (HAQ-DI), assessed with SHAQ|Change from baseline in respiratory function as measured by observed Forced Vital Capacity (FVC)|Change from baseline in observed Carbon Monoxide Diffusing Lung Capacity (DLco [corrected for hemoglobin])",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 2,97.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ACT14604|2016-001028-80|U1111-1179-4690,"November 23, 2016","January 14, 2019","April 1, 2019","October 3, 2016",,"January 14, 2020","Investigational Site Number 8400006, San Francisco, California, United States|Investigational Site Number 8400005, Washington, District of Columbia, United States|Investigational Site Number 8400002, Cleveland, Ohio, United States|Investigational Site Number 8400007, Houston, Texas, United States|Investigational Site Number 0320003, Buenos Aires, Argentina|Investigational Site Number 0320002, Caba, Argentina|Investigational Site Number 0320005, Capital Federal, Argentina|Investigational Site Number 0320001, San Miguel De Tucuman, Argentina|Investigational Site Number 0560001, Gent, Belgium|Investigational Site Number 0560002, Leuven, Belgium|Investigational Site Number 2330001, Tallinn, Estonia|Investigational Site Number 2500003, Montpellier, France|Investigational Site Number 2500004, Paris Cedex 14, France|Investigational Site Number 2500002, Strasbourg Cedex, France|Investigational Site Number 2760003, Bad Nauheim, Germany|Investigational Site Number 2760001, Berlin, Germany|Investigational Site Number 2760002, Köln, Germany|Investigational Site Number 2760004, Ulm, Germany|Investigational Site Number 3800004, Genova, Italy|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800005, Milano, Italy|Investigational Site Number 3800006, Orbassano, Italy|Investigational Site Number 4840001, Chihuahua, Mexico|Investigational Site Number 4840005, Guadalajara, Mexico|Investigational Site Number 4840002, Guadalajara, Mexico|Investigational Site Number 4840003, Monterrey, Mexico|Investigational Site Number 6160001, Poznan, Poland|Investigational Site Number 6160002, Warszawa, Poland|Investigational Site Number 6160003, Wroclaw, Poland|Investigational Site Number 6420003, Bucharest, Romania|Investigational Site Number 6420004, Bucharest, Romania|Investigational Site Number 6420005, Bucuresti, Romania|Investigational Site Number 6420001, Cluj Napoca, Romania|Investigational Site Number 6420002, Targu Mures, Romania|Investigational Site Number 6430002, Kemerovo, Russian Federation|Investigational Site Number 6430005, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430004, Moscow, Russian Federation|Investigational Site Number 6430003, Ufa, Russian Federation|Investigational Site Number 8040001, Kyiv, Ukraine|Investigational Site Number 8040002, Kyiv, Ukraine|Investigational Site Number 8040004, Kyiv, Ukraine|Investigational Site Number 8040003, Kyiv, Ukraine|Investigational Site Number 8260001, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02921971,0,0
40,41,NCT03874715,Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,GEMELLI X,"Active, not recruiting",No Results Available,Type 1 Diabetes Mellitus,Drug: Insulin Aspart SAR341402|Drug: Insulin Aspart|Drug: Insulin glargine U100,Similarity in pharmacokinetics (PK) of SAR341402 and NovoLog:AUClast|Similarity in pharmacokinetics (PK) of SAR341402 and NovoLog: AUC|Similarity in pharmacokinetics (PK) of SAR341402 and NovoLog: Cmax|Immunogenicity: Number of participants with treatment-emergent anti-insulin aspart antibodies (AIAs)|Safety: Hypoglycemic event|Safety: Number of hypoglycemic events per participant per year|Safety: Adverse Events|Comparison of PK parameters between the two arms (alternating administration of SAR341402 and NovoLog and continuous use of NovoLog),Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,184.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EFC15178|U1111-1197-7811,"March 11, 2019",June 2020,June 2020,"March 14, 2019",,"January 27, 2020","Investigational Site Number 8400014, Concord, California, United States|Investigational Site Number 8400001, Temecula, California, United States|Investigational Site Number 8400015, Ventura, California, United States|Investigational Site Number 8400010, Aurora, Colorado, United States|Investigational Site Number 8400029, Waterbury, Connecticut, United States|Investigational Site Number 8400038, Doral, Florida, United States|Investigational Site Number 8400030, Miami, Florida, United States|Investigational Site Number 8400032, New Port Richey, Florida, United States|Investigational Site Number 8400026, Ocoee, Florida, United States|Investigational Site Number 8400033, Palm Harbor, Florida, United States|Investigational Site Number 8400012, Atlanta, Georgia, United States|Investigational Site Number 8400005, Columbus, Georgia, United States|Investigational Site Number 8400009, Roswell, Georgia, United States|Investigational Site Number 8400019, Crystal Lake, Illinois, United States|Investigational Site Number 8400028, Des Moines, Iowa, United States|Investigational Site Number 8400018, Lexington, Kentucky, United States|Investigational Site Number 8400023, Baltimore, Maryland, United States|Investigational Site Number 8400003, Rockville, Maryland, United States|Investigational Site Number 8400013, Waltham, Massachusetts, United States|Investigational Site Number 8400004, Flint, Michigan, United States|Investigational Site Number 8400021, Kansas City, Missouri, United States|Investigational Site Number 8400031, Washington, Missouri, United States|Investigational Site Number 8400036, Omaha, Nebraska, United States|Investigational Site Number 8400017, Las Vegas, Nevada, United States|Investigational Site Number 8400007, New York, New York, United States|Investigational Site Number 8400006, Morehead City, North Carolina, United States|Investigational Site Number 8400035, Rocky Mount, North Carolina, United States|Investigational Site Number 8400034, Jefferson City, Tennessee, United States|Investigational Site Number 8400040, Dallas, Texas, United States|Investigational Site Number 8400042, El Paso, Texas, United States|Investigational Site Number 8400027, Houston, Texas, United States|Investigational Site Number 8400016, Mesquite, Texas, United States|Investigational Site Number 8400041, Waco, Texas, United States",,https://ClinicalTrials.gov/show/NCT03874715,0,1
41,42,NCT01985191,A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients,,Completed,No Results Available,Neoplasm Malignant,Drug: SAR405838|Drug: Pimasertib,"SAR405838 (pimasertib) RP2D assessed by dose-limiting toxicities and pharmacological activities|Changes of tumor dimension by imaging|Overall safety profile of SAR405838 (pimasertib), number of participants with adverse events|Pharmacokinetic parameters for both SAR405838 (pimasertib): the maximum concentration in blood (Cmax)|Pharmacokinetic parameters for both SAR405838 (pimasertib): time to the maximum concentration (Tmax)|Pharmacokinetic parameters for both SAR405838 (pimasertib): area under the curve (AUC), etc.|Biomarker changes in response to SAR405838 (pimasertib) treatment|Genetic status in tumor tissue|Change of the genetic status of circulating tumor DNA","Sanofi|Merck KGaA, Darmstadt, Germany",All,"18 Years and older   (Adult, Older Adult)",Phase 1,26.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TCD13388|2013-002325-33|U1111-1144-8349,November 2013,February 2016,February 2016,"November 15, 2013",,"February 25, 2016","Investigational Site Number 250001, Villejuif Cedex, France|Investigational Site Number 528001, Amsterdam, Netherlands|Investigational Site Number 528003, Rotterdam, Netherlands|Investigational Site Number 528002, Utrecht, Netherlands",,https://ClinicalTrials.gov/show/NCT01985191,0,0
42,43,NCT01086254,SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer,,Completed,No Results Available,Non-small Cell Lung Cancer Stage IV,Drug: Iniparib|Drug: gemcitabine|Drug: cisplatin,"overall response rate (ORR) that is defined in the RECIST 1.1 version, as: complete response rate + partial response rate|progression free survival|overall survival",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 2,119.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TCD11420|2009-017270-21|U1111-1116-5404,May 2010,December 2011,December 2011,"March 15, 2010",,"September 24, 2013","Sanofi-Aventis Investigational Site Number 250002, Caen Cedex, France|Sanofi-Aventis Investigational Site Number 250003, Marseille Cedex 09, France|Sanofi-Aventis Investigational Site Number 250004, Toulouse, France|Sanofi-Aventis Investigational Site Number 250001, Villejuif, France|Sanofi-Aventis Investigational Site Number 276003, Essen, Germany|Sanofi-Aventis Investigational Site Number 276002, Gauting, Germany|Sanofi-Aventis Investigational Site Number 276001, Großhansdorf, Germany|Sanofi-Aventis Investigational Site Number 380003, Livorno, Italy|Sanofi-Aventis Investigational Site Number 380001, Orbassano, Italy|Sanofi-Aventis Investigational Site Number 380002, Rozzano, Italy|Sanofi-Aventis Investigational Site Number 724001, Badalona, Spain|Sanofi-Aventis Investigational Site Number 724002, Barcelona, Spain|Sanofi-Aventis Investigational Site Number 826001, Newcastle Upon Tyne, United Kingdom|Sanofi-Aventis Investigational Site Number 826002, Wolverhampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT01086254,0,0
43,44,NCT03211858,Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine,GEMELLI 1,Completed,Has Results,Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus,Drug: Insulin aspart|Drug: Novolog/Novorapid|Drug: Insulin glargine (HOE901),"Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26|Change in HbA1c From Baseline to Week 52|Percentage of Participants With HbA1c <7% at Week 26 and Week 52|Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 and Week 52|Change in the Mean 24-hour Plasma Glucose Concentration From Baseline to Week 26 and Week 52|Change in Postprandial Plasma Glucose (PPG) Excursion From Baseline to Week 26 and Week 52|Change in 7-Point SMPG Profiles From Baseline to Week 26 and Week 52 Per Time Point|Number of Participants With at Least One Hypoglycemic Event|Number of Hypoglycemia Events Per Participant-Year|Percentage of Participants With Hypersensitivity Reactions and Injection Site Reactions|Percentage of Participants With at Least One Positive Anti-Insulin Aspart Antibodies (AIA) Sample|Percentage of Participants With Treatment Induced, Treatment-Boosted and Treatment-Emergent Anti-insulin Aspart Antibodies (AIAs)",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,597.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EFC15081|2017-000091-28|U1111-1191-5775,"August 2, 2017","July 16, 2018","January 12, 2019","July 7, 2017","August 8, 2019","January 13, 2020","Investigational Site Number 8400040, Little Rock, Arkansas, United States|Investigational Site Number 8400012, Concord, California, United States|Investigational Site Number 8400002, Escondido, California, United States|Investigational Site Number 8400030, Fresno, California, United States|Investigational Site Number 8400004, Greenbrae, California, United States|Investigational Site Number 8400014, La Jolla, California, United States|Investigational Site Number 8400043, Los Angeles, California, United States|Investigational Site Number 8400036, Pomona, California, United States|Investigational Site Number 8400011, Santa Barbara, California, United States|Investigational Site Number 8400013, Ventura, California, United States|Investigational Site Number 8400037, Aurora, Colorado, United States|Investigational Site Number 8400018, Englewood, Colorado, United States|Investigational Site Number 8400031, New Port Richey, Florida, United States|Investigational Site Number 8400027, Ocoee, Florida, United States|Investigational Site Number 8400007, Atlanta, Georgia, United States|Investigational Site Number 8400022, Columbus, Georgia, United States|Investigational Site Number 8400032, Roswell, Georgia, United States|Investigational Site Number 8400038, Arlington Heights, Illinois, United States|Investigational Site Number 8400005, Des Moines, Iowa, United States|Investigational Site Number 8400041, Metairie, Louisiana, United States|Investigational Site Number 8400015, Rockville, Maryland, United States|Investigational Site Number 8400042, Waltham, Massachusetts, United States|Investigational Site Number 8400019, Flint, Michigan, United States|Investigational Site Number 8400003, Omaha, Nebraska, United States|Investigational Site Number 8400024, Henderson, Nevada, United States|Investigational Site Number 8400028, New York, New York, United States|Investigational Site Number 8400025, Morehead City, North Carolina, United States|Investigational Site Number 8400010, Wilmington, North Carolina, United States|Investigational Site Number 8400023, Fargo, North Dakota, United States|Investigational Site Number 8400029, Bend, Oregon, United States|Investigational Site Number 8400033, Chattanooga, Tennessee, United States|Investigational Site Number 8400044, Austin, Texas, United States|Investigational Site Number 8400009, Dallas, Texas, United States|Investigational Site Number 8400035, Dallas, Texas, United States|Investigational Site Number 8400021, Dallas, Texas, United States|Investigational Site Number 8400017, Houston, Texas, United States|Investigational Site Number 8400001, Houston, Texas, United States|Investigational Site Number 8400020, Houston, Texas, United States|Investigational Site Number 8400016, Mesquite, Texas, United States|Investigational Site Number 8400034, Salt Lake City, Utah, United States|Investigational Site Number 8400008, Renton, Washington, United States|Investigational Site Number 8400039, Bridgeport, West Virginia, United States|Investigational Site Number 2460006, Jyväskylä, Finland|Investigational Site Number 2460002, Kuopio, Finland|Investigational Site Number 2460004, Pori, Finland|Investigational Site Number 2460003, Seinäjoki, Finland|Investigational Site Number 2760001, Berlin, Germany|Investigational Site Number 2760006, Essen, Germany|Investigational Site Number 2760004, Heidelberg, Germany|Investigational Site Number 2760005, Oldenburg In Holstein, Germany|Investigational Site Number 2760002, Pirna, Germany|Investigational Site Number 3480012, Balatonfüred, Hungary|Investigational Site Number 3480011, Budapest, Hungary|Investigational Site Number 3480008, Budapest, Hungary|Investigational Site Number 3480001, Budapest, Hungary|Investigational Site Number 3480005, Budapest, Hungary|Investigational Site Number 3480004, Budapest, Hungary|Investigational Site Number 3480007, Debrecen, Hungary|Investigational Site Number 3480003, Nagykanizsa, Hungary|Investigational Site Number 3480010, Nyíregyháza, Hungary|Investigational Site Number 3480009, Szentendre, Hungary|Investigational Site Number 3920009, Fukuyama-Shi, Japan|Investigational Site Number 3920008, Higashiosaka-Shi, Japan|Investigational Site Number 3920007, Kashiwara-Shi, Japan|Investigational Site Number 3920001, Koriyama-Shi, Japan|Investigational Site Number 3920005, Kumamoto-Shi, Japan|Investigational Site Number 3920003, Mito-Shi, Japan|Investigational Site Number 3920010, Osaka-Shi, Japan|Investigational Site Number 3920002, Sagamihara-Shi, Japan|Investigational Site Number 3920004, Shinjuku-Ku, Japan|Investigational Site Number 3920006, Ushiku-Shi, Japan|Investigational Site Number 6160004, Bialystok, Poland|Investigational Site Number 6160003, Krakow, Poland|Investigational Site Number 6160005, Krakow, Poland|Investigational Site Number 6160007, Lublin, Poland|Investigational Site Number 6160006, Nowy Sacz, Poland|Investigational Site Number 6160001, Poznan, Poland|Investigational Site Number 6160002, Warszawa, Poland|Investigational Site Number 6430002, Samara, Russian Federation|Investigational Site Number 6430003, Saratov, Russian Federation|Investigational Site Number 6430001, St. Petersburg, Russian Federation|Investigational Site Number 6430004, Tomsk, Russian Federation","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03211858/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03211858/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03211858,0,1
44,45,NCT02843035,GZ/SAR402671 in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3,LEAP,Recruiting,No Results Available,Gaucher Disease Type 1-Gaucher Disease Type 3,Drug: GZ402671,Number of patients with adverse events|Assessment of pharmacodynamic (PD) parameter: Lyso-glucosylceramide (lyso-GL1)|Assessment of pharmacodynamic (PD) parameter:Glucosylceramide (GL-1) in cerebrospinal fluid (CSF)|Assessment of pharmacodynamic (PD) parameter:Glucosylceramide (GL-1) in plasma|Assessment of pharmacokinetic parameter: Plasma maximum concentration (Cmax)|Assessment of pharmacokinetic parameter: Time at Cmax (Tmax)|Assessment of pharmacokinetic parameter: Area under the curve (AUC)|Assessment of pharmacokinetic parameter: plasma trough concentration (Ctrough)|Assessment of pharmacokinetic parameter: CSF maximum concentration (Cmax)|Assessment of pharmacokinetic parameter: CSF time at Cmax (Tmax)|Assessment of pharmacokinetic parameter: CSF area under the curve (AUC)|Immunogenicity testing as needed for IAR (Cerezyme),"Genzyme, a Sanofi Company|Sanofi",All,"18 Years and older   (Adult, Older Adult)",Phase 2,10.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PDY13949|2014-002550-39|U1111-1156-4278,"January 4, 2017",May 2024,May 2024,"July 25, 2016",,"December 13, 2019","Investigational Site Number 840002, New Haven, Connecticut, United States|Investigational Site Number 840001, Dallas, Texas, United States|Investigational Site Number 276001, Mainz, Germany|Investigational Site Number 392001, Minato-Ku, Japan|Investigational Site Number 826003, Cambridge, United Kingdom|Investigational Site Number 826001, London, United Kingdom|Investigational Site Number 826002, Salford, United Kingdom",,https://ClinicalTrials.gov/show/NCT02843035,0,1
45,46,NCT02345070,Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis,ESTAIR,Completed,No Results Available,Idiopathic Pulmonary Fibrosis,Drug: SAR156597|Drug: placebo,Absolute change from baseline in percent predicted Forced Vital Capacity (FVC)|Proportion of patients with disease progression|Number of deaths (all causes),Sanofi,All,"40 Years and older   (Adult, Older Adult)",Phase 2,327.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",DRI11772|2014-003933-24|U1111-1154-6083,"May 1, 2015","May 22, 2017","August 14, 2017","January 26, 2015",,"June 15, 2018","Investigational Site Number 840003, Phoenix, Arizona, United States|Investigational Site Number 840020, Jacksonville, Florida, United States|Investigational Site Number 840022, Loxahatchee Groves, Florida, United States|Investigational Site Number 840017, Atlanta, Georgia, United States|Investigational Site Number 840008, Decatur, Georgia, United States|Investigational Site Number 840010, Louisville, Kentucky, United States|Investigational Site Number 840009, Minneapolis, Minnesota, United States|Investigational Site Number 840006, Rochester, Minnesota, United States|Investigational Site Number 840026, Chesterfield, Missouri, United States|Investigational Site Number 840001, Lebanon, New Hampshire, United States|Investigational Site Number 840002, Summit, New Jersey, United States|Investigational Site Number 840015, Jamaica, New York, United States|Investigational Site Number 840023, Mineola, New York, United States|Investigational Site Number 840012, New York, New York, United States|Investigational Site Number 840013, Stony Brook, New York, United States|Investigational Site Number 840014, Philadelphia, Pennsylvania, United States|Investigational Site Number 840011, Dallas, Texas, United States|Investigational Site Number 840024, Everett, Washington, United States|Investigational Site Number 032009, Caba, Argentina|Investigational Site Number 032005, Caba, Argentina|Investigational Site Number 032001, La Plata, Argentina|Investigational Site Number 032004, Mendoza, Argentina|Investigational Site Number 032002, San Miguel De Tucumán, Argentina|Investigational Site Number 032007, Vicente Lopez, Argentina|Investigational Site Number 036005, Camperdown, Australia|Investigational Site Number 036004, Darlinghurst, Australia|Investigational Site Number 036002, Frankston, Australia|Investigational Site Number 036003, Murdoch, Australia|Investigational Site Number 036001, Nundah, Australia|Investigational Site Number 124003, Toronto, Canada|Investigational Site Number 124002, Vancouver, Canada|Investigational Site Number 152003, Quillota, Chile|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 152004, Santiago, Chile|Investigational Site Number 152006, Santiago, Chile|Investigational Site Number 152002, Talca, Chile|Investigational Site Number 152007, Viña Del Mar, Chile|Investigational Site Number 170004, Armenia, Colombia|Investigational Site Number 170001, Bogota, Colombia|Investigational Site Number 170005, Cali, Colombia|Investigational Site Number 203002, Hradec Kralove, Czechia|Investigational Site Number 203004, Olomouc, Czechia|Investigational Site Number 203003, Praha 2, Czechia|Investigational Site Number 203001, Praha 4, Czechia|Investigational Site Number 208002, Aarhus C, Denmark|Investigational Site Number 208001, Hellerup, Denmark|Investigational Site Number 250007, Bobigny, France|Investigational Site Number 250002, Lille Cedex, France|Investigational Site Number 250001, Lyon, France|Investigational Site Number 250009, Marseille, France|Investigational Site Number 250005, Montpellier, France|Investigational Site Number 250004, Nice, France|Investigational Site Number 250006, Paris, France|Investigational Site Number 250008, Toulouse, France|Investigational Site Number 250003, Tours, France|Investigational Site Number 276003, Coswig, Germany|Investigational Site Number 276002, Donaustauf, Germany|Investigational Site Number 276004, Gießen, Germany|Investigational Site Number 276005, Hannover, Germany|Investigational Site Number 276001, Heidelberg, Germany|Investigational Site Number 300001, Heraklion, Greece|Investigational Site Number 376001, Haifa, Israel|Investigational Site Number 376004, Kfar Saba, Israel|Investigational Site Number 376002, Petah-Tikva, Israel|Investigational Site Number 376005, Rehovot, Israel|Investigational Site Number 376003, Tel Hashomer, Israel|Investigational Site Number 380003, Catania, Italy|Investigational Site Number 380001, Forlì, Italy|Investigational Site Number 380005, Milano, Italy|Investigational Site Number 380002, Orbassano, Italy|Investigational Site Number 380006, Pisa, Italy|Investigational Site Number 380004, Siena, Italy|Investigational Site Number 410005, Bucheon-Si, Korea, Republic of|Investigational Site Number 410001, Incheon, Korea, Republic of|Investigational Site Number 410006, Seongnam, Korea, Republic of|Investigational Site Number 410002, Seoul, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 484002, Mexico City, Mexico|Investigational Site Number 484001, Monterrey, Mexico|Investigational Site Number 484005, Monterrey, Mexico|Investigational Site Number 484003, San Juan Del Rio, Mexico|Investigational Site Number 620003, Porto, Portugal|Investigational Site Number 620004, Vila Nova De Gaia, Portugal|Investigational Site Number 724003, Barcelona, Spain|Investigational Site Number 724002, Barcelona, Spain|Investigational Site Number 724001, Hospitalet De Llobregat, Spain|Investigational Site Number 724004, Lugo, Spain|Investigational Site Number 724006, Majadahonda, Spain|Investigational Site Number 724005, Palma De Mallorca, Spain|Investigational Site Number 724007, Sabadell, Spain|Investigational Site Number 792005, Ankara, Turkey|Investigational Site Number 792006, Istanbul, Turkey|Investigational Site Number 792001, Istanbul, Turkey|Investigational Site Number 792004, Istanbul, Turkey|Investigational Site Number 792003, Istanbul, Turkey|Investigational Site Number 792002, Izmir, Turkey|Investigational Site Number 826002, Cambridge, United Kingdom|Investigational Site Number 826003, Exeter, United Kingdom|Investigational Site Number 826004, Leicester, United Kingdom|Investigational Site Number 826001, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02345070,0,0
46,47,NCT03920007,Study of Subretinally Injected SAR439483 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D,,Recruiting,No Results Available,Leber's Congenital Amaurosis,Drug: SAR439483|Drug: SAR439483 Diluent Solution|Drug: Prednisone|Drug: Triamcinalone Acetonide|Drug: 1% Prednisolone|Drug: Trimethoprim/polymyxin B,Number of participants with adverse events (AEs) from baseline up to the end of the observation period|Number of participants with AEs from baseline up to the end of the safety follow-up period|Change in best -corrected visual acuity (BCVA)|Change in sensitivity,Sanofi,All,"6 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,15.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DFI14738|U1111-1200-1308,"September 12, 2019",March 2021,March 2022,"April 18, 2019",,"November 27, 2019","Investigational Site Number 8400001, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03920007,0,0
47,48,NCT04000282,First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma,,Recruiting,No Results Available,Plasma Cell Myeloma,Drug: SAR442085,The maximum tolerated dose (MTD) of SAR442085 (Part A)|Recommended Phase 2 dose (RP2D) (Part A)|Overall response rate (Part B)|Treatment-emergent adverse events (AEs)/serious adverse events (SAE) (Both Part A and B)|PK parameters of SAR442085: Cmax (Both Part A and B)|PK parameters of SAR442085: Tmax (Both Part A and B)|PK parameters of SAR442085: AUC (Both Part A and B)|Anti-drug antibody (ADA) against SAR442085 (Both Part A and B)|Progression-free survival (Part B)|Duration of response (Part B),Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 1,78.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TED16132|2019-001018-40|U1111-1223-4410,"June 13, 2019",February 2022,February 2022,"June 27, 2019",,"January 27, 2020","Investigational Site Number 8400002, Duarte, California, United States|Investigational Site Number 8400005, Rochester, Minnesota, United States|Investigational Site Number 8400001, New York, New York, United States|Investigational Site Number 8400004, Milwaukee, Wisconsin, United States|Investigational Site Number 2500001, Toulouse Cedex 9, France|Investigational Site Number 7240002, Hospitalet De Llobregat, Spain|Investigational Site Number 7240001, Salamanca, Spain",,https://ClinicalTrials.gov/show/NCT04000282,0,0
48,49,NCT01307319,Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies,,Completed,Has Results,Seasonal Allergic Rhinitis|SAR,Drug: BDP HFA|Drug: Placebo nasal aerosol,Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Reflective Total Nasal Symptom Score (rTNSS) During the Two Weeks of Treatment|Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Instantaneous Total Nasal Symptom Score (iTNSS) During the Two Weeks of Treatment,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",All,6 Years to 11 Years   (Child),Phase 3,715.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BDP-AR-305,March 2011,July 2011,August 2011,"March 2, 2011","February 20, 2015","February 20, 2015","Teva Clinical Study Site, Oxford, Alabama, United States|Teva Clinical Study Site, Bell, California, United States|Teva Clinical Study Site, Costa Mesa, California, United States|Teva Clinical Study Site, Mission Viejo, California, United States|Teva Clinical Study Site, Orange, California, United States|Teva Clinical Study Site, Paramount, California, United States|Teva Clinical Study Site, San Diego, California, United States|Teva Clinical Study Site, San Diego, California, United States|Teva Clinical Study Site, Stockton, California, United States|Teva Clinical Study Site, Centennial, Colorado, United States|Teva Clinical Study Site, Colorado Springs, Colorado, United States|Teva Clinical Study Site, Gainesville, Georgia, United States|Teva Clinical Study Site, Lawrenceville, Georgia, United States|Teva Clinical Study Site, Savannah, Georgia, United States|Teva Clinical Study Site, Stockbridge, Georgia, United States|Teva Clinical Study Site, Indianapolis, Indiana, United States|Teva Clinical Study Site, Bethesda, Maryland, United States|Teva Clinical Study Site, Minneapolis, Minnesota, United States|Teva Clinical Study Site, Plymouth, Minnesota, United States|Teva Clinical Study Site, Columbia, Missouri, United States|Teva Clinical Study Site, Rolla, Missouri, United States|Teva Clinical Study Site, Warrensburg, Missouri, United States|Teva Clinical Study Site, Bozeman, Montana, United States|Teva Clinical Study Site, Brick, New Jersey, United States|Teva Clinical Study Site, High Point, North Carolina, United States|Teva Clinical Study Site, Oklahoma City, Oklahoma, United States|Teva Clinical Study Site, Portland, Oregon, United States|Teva Clinical Study Site, Blue Bell, Pennsylvania, United States|Teva Clinical Study Site, Collegeville, Pennsylvania, United States|Teva Clinical Study Site, Philadelphia, Pennsylvania, United States|Teva Clinical Study Site, Pittsburgh, Pennsylvania, United States|Teva Clinical Study Site, Charleston, South Carolina, United States|Teva Clinical Study Site, Orangeburg, South Carolina, United States|Teva Clinical Study Site, Austin, Texas, United States|Teva Clinical Study Site, Dallas, Texas, United States|Teva Clinical Study Site, Dallas, Texas, United States|Teva Clinical Study Site, El Paso, Texas, United States|Teva Clinical Study Site, Ft. Worth, Texas, United States|Teva Clinical Study Site, Houston, Texas, United States|Teva Clinical Study Site, Kerrville, Texas, United States|Teva Clinical Study Site, New Braunfels, Texas, United States|Teva Clinical Study Site, San Antonio, Texas, United States|Teva Clinical Study Site, Waco, Texas, United States|Teva Clinical Study Site, Burke, Virginia, United States|Teva Clinical Study Site, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01307319,0,0
49,50,NCT03376802,A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects,,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: SAR425899|Drug: Placebo,"Sleep energy expenditure|Total daily energy expenditure|Resting energy expenditure|Basal energy expenditure|Respiratory quotient (RQ)|Fat mass and fat-free mass|Diet Induced Thermogenesis (DIT)|Fasting plasma glucose|HbA1c|Lipid biomarker (free fatty acids, triglycerides, total cholesterol, HDL-/LDL-cholesterol)|Ketone bodies|Adverse events|Pharmacokinetics",Sanofi,All,18 Years to 50 Years   (Adult),Phase 1,24.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",PDY15012|U1111-1191-5658,"April 18, 2018","December 27, 2018","December 27, 2018","December 19, 2017",,"March 5, 2019","Investigational Site Number 8400001, Orlando, Florida, United States|Investigational Site Number 8400002, Baton Rouge, Louisiana, United States",,https://ClinicalTrials.gov/show/NCT03376802,0,1
